Introduction
Streptococcus pneumoniae is an important pathogen, being a significant cause of bacterial pneumonia and otitis media, and associated with a high degree of morbidity and mortality. The global spread of penicillin-resistant and multiply antibiotic-resistant isolates of S. pneumoniae within the last 20 years has been reported by a number of investigators. [1] [2] [3] [4] [5] [6] [7] [8] Goldstein et al. (1996) , in a survey of 1856 strains of S. pneumoniae, reported resistance rates to penicillin and erythromycin of 2-45% in western Europe and 10-43% in the USA, whilst Baquero et al. (1998) reported rates of penicillin resistance of 6-54% and approximately 30%, respectively. 1, 4 Doern et al. (1996) , in a survey of 1527 clinical isolates from 30 medical centres in the USA, reported an incidence of penicillin-non-susceptible strains of 24%. 9 This increase in the prevalence of penicillin-resistant S. pneumoniae strains has led to a reappraisal of the choice of optimal drug therapy for infections caused by this organism, particularly those of the upper and lower respiratory tract, since many of these infections require empirical treatment. 3, 5 As a result, there is a need for continual and comprehensive analyses of the activities of current and new antibiotic therapies against S. pneumoniae in studies involving a large number of clinical isolates.
Some older, established fluoroquinolones, such as ciprofloxacin, do not have sufficient activity against S. pneumoniae and, consequently, have not been regarded as treatment options for this pathogen. However, the newer fluoroquinolones, such as levofloxacin and trovafloxacin, have greater activity against S. pneumoniae and may provide a useful therapeutic alternative. 10, 11 This study was conducted to compare the antipneumococcal activity of the fluoroquinolone levofloxacin with currently available to the other study drugs. All -lactam antibiotics, erythromycin and trimethoprim-sulphamethoxazole were less active against penicillin-resistant strains, indicating that these may be suboptimal agents for empirical therapy for suspected S. pneumoniae infections in these patient populations. However, levofloxacin, ofloxacin, clindamycin and vancomycin were equally active against penicillin-susceptible and -resistant strains. These data suggest that the efficacy of levofloxacin should be examined in both adult and paediatric S. pneumoniae infections involving body sites where levofloxacin concentrations >2 mg/L can be achieved safely.
In-vitro activity of levofloxacin against

Materials and methods
Strains
The study strains comprised a collection of 202 isolates of S. pneumoniae of which 56% were susceptible to penicillin, 34% intermediate and 10% resistant (Table I ). These organisms (60% nasopharyngeal, 40% middle ear) were obtained from otherwise healthy children at child care centres in urban and rural Nebraska and at a paediatric clinic in rural Kentucky from March 1994 to July 1995. 
Susceptibility tests
Results
The activities of the study drugs were compared by grouping them in the following classes: fluoroquinolones, -lactams and miscellaneous agents.
Fluoroquinolones
Levofloxacin was two-fold more potent than ofloxacin, and equivalent to or two-fold more potent than ciprofloxacin against all strains, including both penicillin-susceptible and -resistant strains (Tables I and II) . The activity of the fluoroquinolones was undiminished against both penicillinintermediate and -resistant strains, many of which were multiply resistant, being resistant also to trimethoprimsulphamethoxazole and erythromycin (Table III) . In the absence of NCCLS interpretative criteria, a susceptible breakpoint concentration of р1 mg/L was used for ciprofloxacin as this is the NCCLS breakpoint for other species. The percentage susceptibility to each fluoroquinolone was levofloxacin, 98%; ofloxacin, 93%; and ciprofloxacin, 61% (Table III) .
-Lactams
The activity of the -lactam antibiotics is shown in Tables II  and III . Ceftriaxone was less affected by increasing penicillin resistance than the other -lactams and was therefore the most potent of this group of agents. However, only five of the 20 penicillin-resistant strains (25%) were ceftriaxone-susceptible (Table III) . Amoxycillin was more potent than the oral cephalosporins, cefpodoxime and cefaclor, and the carbacephem, loracarbef. Compared with ceftriaxone, amoxycillin was more potent only against the penicillin-susceptible strains. All penicillin-susceptible strains were inhibited by amoxycillin 0.06 mg/L and ceftriaxone 0.12 mg/L.
Miscellaneous agents
All strains were susceptible to vancomycin and most penicillin-intermediate and -resistant strains were also susceptible to clindamycin (Table III) No NCCLS breakpoints available for these agents against pneumococci. The NCCLS recommends that susceptibility to penicillin be taken to indicate susceptibility to these agents. Strains which are intermediate or resistant to these agents cannot be evaluated.
Discussion
In this study, levofloxacin was the most potent of the flu o r oquinolones tested, with 98% of all isolates inhibited by a concentration of 2 mg/L, compared with 93% for ofloxacin and 61% for ciprofloxacin. As expected, the potency of all -lactam antibiotics decreased as penicillin resistance increased. In contrast, the activity of levofloxacin, ofloxacin and ciprofloxacin against non-susceptible strains was similar to their activity against penicillin-susceptible strains. Thus, the penicillin susceptibility of the strain did not affect the activity of the fluoroquinolones. This result is in keeping with those of previous studies which have shown that fluoroquinolone activity against pneumococci is not affected by the penicillin susceptibility of the strain. 13, 14 Although superficial interpretation of the data suggests that the activities of levofloxacin and ofloxacin were similar (98% versus 93% susceptibility, respectively), the activity of these agents differed markedly at a concentration of 1 mg/L, with 93% of strains being inhibited by levofloxacin and only 20% inhibited by ofloxacin (Table I) .
Erythromycin and trimethoprim-sulphamethoxazole can be considered as alternatives to penicillins in areas where penicillin-susceptible strains are endemic.
9 , 1 5 , 1 6 H o wever, the high degree of resistance to these compounds among penicillin-intermediate and -resistant strains indicates that they may not be suitable agents for empirical use in patient populations where such strains are relatively common. In contrast, vancomycin and clindamycin were highly active against the collection of isolates tested, indicating that they may be suitable agents for empirical therapy of presumed pneumococcal infections in this patient population. Similar findings were obtained by Barry et al. (1994) who also reported that pneumococcal strains with decreased susceptibility to penicillin showed decreased susceptibility to other antibiotics, including trimethoprim-sulphamethoxazole, erythromycin and cephalosporins. 17 The importance of evaluating alternative therapies for the empirical treatment of S. pneumoniae infections is shown by the high incidence of penicillin-non-susceptible strains in this study. Boken et al. (1995) also reported a high incidence of penicillin-non-susceptible strains in a study of 54 children at a childcare centre in Omaha, NB. 18 Of 32 S. pneumoniae nasopharyngeal isolates, 23 (72%) had decreased susceptibility to penicillin, 17 of which (74%) had an MIC у2 mg/L, and seven (22%) were penicillinintermediate. 18 In conclusion, the results of this susceptibility study indicate that if tissue and body fluid concentrations Ͼ2 mg/L can be achieved safely, levofloxacin may be a more suitable agent than currently available fluoroquinolones and other agents for treating infections caused by both wild-type and multiply antibiotic-resistant strains of S. pneumoniae.
